Back to Journals » OncoTargets and Therapy » Volume 11

Four cycles of adriamycin and cyclophosphamide followed by four cycles of docetaxel (NSABP-B27) with concomitant trastuzumab as neoadjuvant therapy for high-risk, early-stage, HER2-positive breast cancer patients

Total article views   HTML views PDF downloads Totals
14,594 Dovepress* 9,742+ 959 10,701
PubMed Central* 4,852 274 5,126
Totals 14,594 1,233 15,827
*Since 11 April 2018

View citations on PubMed Central and Google Scholar